Please use this identifier to cite or link to this item:
Title: Current state of clinical trials regarding liver transplant rejection
Authors: El Masri, Jad
El Ayoubi, Lemir Majed
Zreika, Bachir
Adhami, Fouad
El Masri, Diala
El Hage, Said
Abou-Jaoudé, Maroun
Affiliations: Faculty of Medicine 
Keywords: Clinical trials
Transplant rejection
Issue Date: 2022
Publisher: Elsevier
Part of: Transplant Immunology
Volume: 70
Liver transplant (LT) is the second most common transplant intervention. The rate of acute cellular rejection (ACR) is 15–25% after LT, while being higher in chronic rejection (CR). Clinical trials had a major role in getting more potent and selective immunosuppressive medications. Our study plays an important role by evaluating and tracking clinical trials related to liver transplant rejection, focusing on interventional therapeutic trials.

On October 28, we searched for interventional clinical trials related to liver transplant rejection. A total of 27 clinical trials included in this study. Characteristics on each trial were collected, and availability of linked publications was searched using Medline/PubMed and Embase/Scopus. Content of publications was reviewed and main findings were summarized.

Majority of trials were completed (15 out of 27). Eleven trials had between 11 and 50 participants, and 10 had above 100. The study duration was between 1 and 4 years for the majority of trials (16 trials), with an average of 3.77 years. Most of the trials were done in Europe/UK/Russia (n = 12). The results were provided in 9 trials but published in 4, showing the possible tolerogenic efficacy of MSC in liver transplantation, increased success of immunosuppression (IS) withdrawal after sirolimus addition, efficacy of Alemtuzumab, normal graft function and stability within 1 year of immunosuppression withdrawal.

This study revealed a low number of trials, lack of variety in location and low publishing rates. The focus of trials was mainly towards side effects and safety of immunosuppressants, and their withdrawal. These trials reached results that must be built on to reach definitive guidelines and treatment strategies. This highlights the need for better management of human and financial resources, in order to reach new and more effective therapeutic strategies, leading to the decrease in rate of LTR.
ISSN: 09663274
DOI: 10.1016/j.trim.2021.101522
Ezproxy URL: Link to full text
Type: Journal Article
Appears in Collections:Faculty of Medicine

Show full item record


checked on Dec 3, 2022

Record view(s)

checked on Dec 9, 2022

Google ScholarTM


Dimensions Altmetric

Dimensions Altmetric

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.